Alpha Tau Medical
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Alpha Tau Medical (DRTS) | 1.09B | -11.30 | 24.64 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 7.6% below Morningstar's fair value estimate.
Fair value
Alpha Tau Medical Ltd earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% premium over our quantitative fair value estimate of $12.65 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.
The company's unfavorable dividend structure decreases our fair value estimate. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. For example, the firm's forward dividend yield of 0% sits in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which contributes to our view that shares are overvalued.
The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -4.0%, for example, falls in the bottom 20% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
Alpha Tau Medical discussion 0 comments